• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

immunotherapy

baton handoff in track and field race
Biotech

Menarini gets Georgiamune preclinical cancer drug in $1B deal

Maryland-based Georgiamune has licensed a preclinical cancer drug candidate to Stemline Therapeutics, which is owned by Italy's Menarini Group.
Michael Gibney Oct 22, 2026 10:50am
In Laboratory Over the Shoulder View of Scientist in Protective Clothes Doing Research on a Personal Computer

Using tumor ‘avatar’ to predict patients’ immunotherapy response

Oct 21, 2026 11:50am
european euros

Nouscom bags $135M for pivotal therapeutic cancer vaccine trial

Oct 19, 2026 2:00am
closed shuttered shut down closed

Adecto blames ‘risk-adverse funding environment’ for closing

Oct 2, 2026 3:53am
man with skin cancer on head

Highlight Therapeutics illuminates positive data in skin cancer

Sep 30, 2026 9:00am
pipeline pipes RD research

PDS halts ph. 3 cancer therapy to focus on colorectal contender

Aug 13, 2026 9:55am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings